GC Green Cross Q3 Operating Profit Hits 50.7 Billion KRW, Surpassing Last Year's Results

[Asia Economy, reporter Cho Hyun] GC Green Cross announced in a regulatory filing on November 2 that its consolidated operating profit for the third quarter of this year reached 50.7 billion KRW, a 37.1% increase compared to the same period last year, based on provisional figures. This amount surpasses the company's total annual operating profit from last year, and marks the first time in 24 quarters since the third quarter of 2014 that quarterly operating profit has exceeded 50 billion KRW.

Sales reached 419.6 billion KRW, up 14.5% year-on-year. This is the company's highest quarterly sales ever, surpassing the previous record of 366.5 billion KRW set in the third quarter of last year. Net profit rose by 182.8% to 63.4 billion KRW.

On a cumulative basis through the third quarter of this year, the company recorded sales of 1.0874 trillion KRW, operating profit of 72.5 billion KRW, and pre-tax profit of 95.9 billion KRW, with all key financial indicators showing growth.

The company explained that these strong results were achieved thanks to solid performance across all business segments, despite the impact of the COVID-19 pandemic.

By segment, vaccine sales reached 127 billion KRW, blood products 103.4 billion KRW, general pharmaceuticals 73.7 billion KRW, and consumer healthcare 39.1 billion KRW. Notably, vaccine sales increased by 21.5% year-on-year due to rising demand in the Northern Hemisphere, while the consumer healthcare business saw its sales volume expand by approximately 31% compared to a year earlier.

This content was produced with the assistance of AI translation services.